Ipamorelin 5mg

Ipamorelin 5mg Research Peptide UK

Ipamorelin 5mg is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular formula C38H49N9O5, and a molecular weight of 711.85 g/mol. It is classified as a Growth Hormone Releasing Peptide (GHRP) and acts as a selective agonist at GHS-R1a, the ghrelin receptor, on anterior pituitary somatotroph cells. The ipamorelin 5mg research peptide is the most receptor-selective GHRP available for UK laboratory research.

The defining research characteristic of ipamorelin 5mg is its receptor selectivity compared to other GHRPs. Unlike GHRP-6 and GHRP-2, ipamorelin has been investigated in published research for its comparatively selective GHS-R1a pathway activity relative to earlier GHRP analogues. This clean pharmacological profile allows researchers to attribute observed outcomes specifically to GH pathway activity, which is a critical advantage when the experimental question requires pathway-specific, attributable data.

The GHS-R1a activation mechanism follows the pathway: GHS-R1a binding leads to Gq protein stimulation, which activates phospholipase C (PLC), generating IP3 and DAG, which elevates intracellular calcium, ultimately triggering pulsatile GH secretion from somatotroph cells. This ghrelin receptor pathway is entirely distinct from the GHRH receptor pathway targeted by CJC-1295 Without DAC 10mg, Ipamorelin and GHRH analogues target distinct signalling pathways and have been evaluated separately in experimental literature..

The 5mg format of ipamorelin is appropriate for pilot studies, method validation, and first-time GHRP research. For established programmes requiring full dose-response gradients, multi-arm designs, and extended single-batch longitudinal studies, Ipamorelin 10mg provides the advanced format. For downstream growth factor research alongside ipamorelin protocols, IGF-1 LR3 1mg targets the IGF-1 receptor axis, providing a mechanistically distinct complement. For complete combined protocol guidance, see the ipamorelin 5mg research guide on the Ascend Peptides UK blog.

All ipamorelin 5mg batches are independently tested by Janoshik. HPLC purity confirmed at greater than or equal to 98%, LC-MS confirms C38H49N9O5 at 711.85 g/mol. Verifiable Certificate of Analysis.

For laboratory handling purposes, the lyophilised material may be reconstituted using bacteriostatic water or another suitable buffered aqueous solution depending on analytical protocol requirements. Store lyophilised material at -20°C and avoid repeated freeze-thaw cycles.

WADA Status: Prohibited at all times.

DISCLAIMER: For in-vitro research only. Not an MHRA-licensed medicine.